podcasts Ratings /ratings/en/research-insights/podcasts/s-p-pharma-dose-episode-30-rebates-and-pharma-supply-chain content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

In This List

S&P Pharma Dose - Episode 30: Rebates And Pharma Supply Chain

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

COMMENTS

ESG Concerns In Oil And Gas Sectors Led To A Surge In Downgrade Pressure In January, Which Was Realized By Mid-February

COMMENTS

As European Hotels Grapple With Prolonged Restrictions, Are Operators And Landlords Sharing The Pain?

COMMENTS

Pharma Outlook: Eighth Straight Year Of Credit Deterioration In 2021

Listen: S&P Pharma Dose - Episode 30: Rebates And Pharma Supply Chain

Healthcare analysts Tulip Lim and Ji Liu drop in on the S&P Pharma Guy, Arthur Wong, to talk how HHS's proposal to ban rebating from the Medicare market. What's the impact on the ratings of the pharma supply chain players?

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back